Raymond James & Associates’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $337K | Buy |
|
|||||
|
2024
Q2 | $288K | Buy |
|
|||||
|
2024
Q1 | $272K | Buy |
|
|||||
|
2023
Q4 | $257K | Sell |
|
|||||
|
2023
Q3 | $500K | Buy |
|
|||||
|
2023
Q2 | $398K | Buy |
|
|||||
|
2023
Q1 | $300K | Buy |
|
|||||
|
2022
Q4 | $288K | Buy |
|
|||||
|
2022
Q3 | $222K | Buy |
|
|||||
|
2022
Q2 | – | Sell |
|
|||||
|
2022
Q1 | $341K | Sell |
|
|||||
|
2021
Q4 | $456K | Sell |
|
|||||
|
2021
Q3 | $531K | Buy |
|
|||||
|
2021
Q2 | $561K | Sell |
|
|||||
|
2021
Q1 | $555K | Sell |
|
|||||
|
2020
Q4 | $685K | Sell |
|
|||||
|
2020
Q3 | $794K | Sell |
|
|||||
|
2020
Q2 | $810K | Buy |
|
|||||
|
2020
Q1 | – | Sell |
|
|||||
|
2019
Q4 | $1.76M | Sell |
|
|||||
|
2019
Q3 | $1.4M | Buy |
|
|||||
|
2019
Q2 | $269K | Sell |
|
|||||
|
2019
Q1 | $1.99M | Sell |
|
|||||
|
2018
Q4 | $2.36M | Sell |
|
|||||
|
2018
Q3 | $3.39M | Buy |
|
|||||
|
2018
Q2 | $2.9M | Sell |
|
|||||
|
2018
Q1 | $2.85M | Sell |
|
|||||
|
2017
Q4 | $4M | Buy |
|
|||||
|
2017
Q3 | $1.78M | Sell |
|
|||||
|
2017
Q2 | $2.91M | Sell |
|
|||||
|
2017
Q1 | $3.21M | Buy |
|
|||||
|
2016
Q4 | $2.09M | Buy |
|
|||||
|
2016
Q3 | $2.11M | Sell |
|
|||||
|
2016
Q2 | $2.17M | Sell |
|
|||||
|
2016
Q1 | $2.35M | Sell |
|
|||||
|
2015
Q4 | $3.56M | Sell |
|
|||||
|
2015
Q3 | $4.18M | Sell |
|
|||||
|
2015
Q2 | $7.11M | Sell |
|
|||||
|
2015
Q1 | $7.34M | Sell |
|
|||||
|
2014
Q4 | $6.68M | Sell |
|
|||||
|
2014
Q3 | $6.83M | Buy |
|
|||||
|
2014
Q2 | $6.66M | Buy |
|
|||||
|
2014
Q1 | $5.61M | Sell |
|
|||||
|
2013
Q4 | $9.19M | Sell |
|
|||||
|
2013
Q3 | $8.14M | Sell |
|
|||||
|
2013
Q2 | $7.79M | Buy |
|